Discontinuation of KRP-203 Development and Return of Development Rights
First written in FY2018-Q3. 1 of 3 entries say "Cited as achieved", first in FY2019. Latest entry: FY2021-Q2.
No other company in this theme has enough history to compare yet.
- FY2021-Q2AdvancedAnnual report
「In addition, in September of the same year, we entered into an agreement with Priothera for the transfer of intellectual property and other assets relating to the immunomodulator KRP-203, and transferred the intellectual property, active pharmaceutical ingredients and other assets related to the development and marketing of the product.」
For KRP-203, as the next step following the discontinuation of development and return of the rights, the intellectual property, active pharmaceutical ingredients and other assets were transferred to Priothera. - FY2019Cited as achievedAnnual report
「Decline in sales due to the licensee's discontinuation of KRP-203 development and the temporary suspension of Desalex supply」
The discontinuation of KRP-203 development and the return of the development rights were cited as factors behind performance falling below expectations. - FY2018-Q3First statedAnnual report
「For KRP-203, an immunomodulator, Novartis, the licensee, decided to discontinue development for strategic reasons, and we were to receive the return of the development rights and other rights granted to the company.」
Novartis discontinued development of KRP-203 and returned the development rights and other rights that had been granted to it.